The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.
|Articles|March 23, 2021
Rheumatoid Arthritis Quiz: Treating Rheumatoid Arthritis in Pregnancy
Author(s)Ingrid Torjesen
Most women experience a decrease in the severity of their rheumatoid arthritis (RA) symptoms during pregnancy, but some may need ongoing treatment. Test your knowledge of the treatment of RA during pregnancy.
Advertisement
Is the following statement true or false?
High disease activity impairs fertility and increases the risk of adverse pregnancy outcomes.
Advertisement
Related to this article
August 2026 rheumatology highlights include FDA approval of brepocitinib for dermatomyositis and garetosmab-grts for FOP, and new trial data.
In RA-BRIDGE and RA-BRANCH, baricitinib failed to demonstrate VTE noninferiority in patients with RA enriched for thromboembolic risk factors.
A Phase 2a basket trial produced ACR50 responses in 71% of refractory RA patients at 6 months.
Advertisement
Advertisement